Acumen Pharmaceuticals, Inc. advances two new Enhanced Brain Delivery candidates for Alzheimer treatment

Acumen Pharmaceuticals, Inc. advances two new Enhanced Brain Delivery candidates for Alzheimer treatment
Acumen targets Alzheimer pipeline

Acumen Pharmaceuticals, Inc. announced the nomination of two candidates using its Enhanced Brain Delivery technology for development in the treatment of Alzheimer disease, as part of a collaboration with JCR Pharmaceuticals.

The move signals a step forward in early-stage research targeting unmet needs in neurodegenerative disorders. Additional details about the specific candidates or development timelines were not disclosed.

Acumen has previously advanced brain health research as dementia rates continue to rise. The company encouraged public engagement during Alzheimer and Brain Awareness Month. The latest candidate nominations expand on earlier efforts to address neurological conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.